Probiotics: Delineation of prophylactic and therapeutic benefits

Journal of Medicinal Food

Volumn 12, Issue 2, 2009, Pages 219-235

  Kaur, Indu Pal ^a   Kuhad, Anurag ^a   Garg, Amita ^a   Chopra, Kanwaljit ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Fructooligosaccharides; Lactobacillus; Prebiotics; Probiotics; Streptococcus thermophilus

Indexed keywords

ANTIBIOTIC AGENT; BALSALAZIDE; CHARCOAL; DEXTRAN; FRUCTOSE OLIGOSACCHARIDE; INULIN; LACTIPAN; LAKCID L; MESALAZINE; METRONIDAZOLE; NICOTINAMIDE; PREBIOTIC AGENT; PROBIOTIC AGENT; PYRIDOXINE; RIBOFLAVIN; SYNBIOTIC AGENT; THIAMINE; TRYPTOPHAN; UNCLASSIFIED DRUG; VSL3;

AGING; ANGELICA; ATOPIC DERMATITIS; AUTISM; BIFIDOBACTERIUM ANIMALIS; BIFIDOBACTERIUM BIFIDUM; CHRONIC FATIGUE SYNDROME; CHRONIC GASTRITIS; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; COLON CANCER; CROHN DISEASE; DENTAL CARIES; DIARRHEA; ENTERITIS; ENTEROCOCCUS; ESCHERICHIA COLI; FATIGUE; GENE TRANSFER; HELICOBACTER INFECTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ILEITIS; IMMUNITY; IMMUNOMODULATION; INFANTILE DIARRHEA; KIDNEY INFECTION; LACTASE DEFICIENCY; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS FERMENTUM; LACTOBACILLUS REUTERI; LACTOBACILLUS RHAMNOSUS; MILK ALLERGY; NEPHROLITHIASIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OSTEOPOROSIS; PEPTIC ULCER; PRIORITY JOURNAL; PROPHYLAXIS; RESPIRATORY TRACT INFECTION; REVIEW; RISK REDUCTION; ROTAVIRUS; SACCHAROMYCES BOULARDII; STREPTOCOCCUS THERMOPHILUS; SURGICAL INFECTION; TRAVELLER DIARRHEA; TREATMENT DURATION; ULCERATIVE COLITIS; URETHRITIS; UROGENITAL TRACT INFECTION; VAGINITIS;

BACTERIAL INFECTIONS; BIFIDOBACTERIUM; HUMANS; INTESTINAL DISEASES; LACTOBACILLUS; PROBIOTICS;

BACTERIA (MICROORGANISMS); BIFIDOBACTERIUM; LACTOBACILLUS; STREPTOCOCCUS THERMOPHILUS;

EID: 67649531368     PISSN: 1096620X     EISSN: None     Source Type: Journal    
DOI: 10.1089/jmf.2007.0544     Document Type: Review

References (176)

1. Caramia G: Probiotics: from Metchnikoff to the current preventive and therapeutic possibilities. Pediatr Med Chir 2004;26: 19-33.
2. Lilly DM, Stillwell RH: Probiotics: growth promoting factors produced by microorganisms. Science 1965;47:747-748.
3. Fuller R: Probiotics in man and animals. J Appl Bacteriol 1989;66:365-378.
4. Meier R, Lochs H: Pre- and probiotics. Ther Umsch 2007;64: 161-169.
5. Scholz-Ahrens KE, Ade P, Marten B, et al.: Prebiotics, probiotics, and synbiotics affect mineral absorption, bone mineral content, and bone structure. J Nutr 2007;137(3 Suppl 2):838S-846S.
6. + CD45RBhigh T cell-mediated inflammatory bowel disease by inhibition of disordered T cell activation. Clin Immunol 2007; 123:30-39.
7. Geier MS, Butler RN, Giffard PM, Howarth GS: Lactobacillus fermentum BR11, a potential new probiotic, alleviates symptoms of colitis induced by dextran sulfate sodium (DSS) in rats. Int J Food Microbiol 2007;114:267-274.
8. Fan YJ, Chen SJ, Yu YC, Si JM, Liu B: A probiotic treatment containing Lactobacillus, Bifidobacterium and Enterococcus im- proves IBS symptoms in an open label trial. J Zhejiang Univ Sci B 2006;7:987-991.
9. Astegiano M, Pellicano R, Terzi E, Simondi D, Rizzetto M: Treatment of irritable bowel syndrome. A case control experience. Minerva Gastroenterol Dietol 2006;52:349-358.
10. Colecchia A, Vestito A, La Rocca A, Pasqui F, Nikiforaki A, Festi D: Effect of a symbiotic preparation on the clinical manifestations of irritable bowel syndrome, constipation-variant. Results of an open, uncontrolled multicenter study. Minerva Gas-troenterol Dietol 2006;52:359-363.
11. Campieri M, Rizzello F, Venturi A: Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: a randomized controlled study vs. mesalamine [abstract]. Gastroenterology 2000;118: G4179.
12. Kaur IP, Chopra K, Saini A: Probiotics potential pharmaceutical applications. Eur J Pharm Sci 2002;15:1-9.
13. Kaur IP, Anurag, Chopra K: Probiotics in paediatric disorders. Gut flora, potential agents and the road ahead. Int J Pharm Med 2006;20:37-48.
14. Rolfe RD: The role of probiotic cultures in the control of gastrointestinal health. J Nutr 2000;130(2S Suppl):396S-402S.
15. Broussard EK, Surawicz CM: Probiotics and prebiotics in clinical practice. Nutr Clin Care 2004;7:104-113.
16. Madsen K, Cornish A, Soper P: Probiotic bacteria enhances murine and human intestinal epithelial barrier function. Gas-troenterology 2001;121:580-591.
17. Hill JO, Peters JC: Biomarkers and functional foods for obesity and diabetes. Br J Nutr 2002;88(Suppl 2):S213-S218.
18. O'Hara AM, Shanahan F: Mechanisms of action of probiotics in intestinal diseases. Sci World J 2007;7:31-46.
19. O'Sullivan GC, Kelly P, O'Halloran S: Probiotics: an emerging therapy. Curr Pharm Des 2005;11:3-10.
20. Balcázar JL, Vendrell D, de Blas I, Ruiz-Zarzuela I, Gironés O, Muzquiz JL: In vitro competitive adhesion and production of antagonistic compounds by lactic acid bacteria against fish pathogens. Vet Microbiol 2007;122:373-380.
21. Gollop N, Zakin V, Weinberg ZG: Antibacterial activity of lactic acid bacteria included in inoculants for silage and in silages treated with these inoculants. J Appl Microbiol 2005;98:662- 666.
22. Schultz M, Linde H, Staudner H, Lehn N, Falk W, Schoelmerich J: Oral administration of Lactobacillus GG induces an anti-inflammatory, Th-2 mediated systemic immune response towards intestinal organisms [abstract]. Gastroenterology 2000;118: A4180.
23. Vesterlund S, Paltta J, Karp M, Ouwehand AC: Measurement of bacterial adhesion - in vitro evaluation of different methods. J Microbiol Methods 2005;60:225-233.
24. Vizoso Pinto MG, Schuster T, Briviba K, Watzl B, Holzapfel WI, Franz CM: Adhesive and chemokine stimulatory properties of potentially probiotic Lactobacillus strains. J Food Prot 2007;70:125-134.
25. Paton AW, Morona R, Paton JCS: Designer probiotics for prevention of enteric infection. Nat Rev Microbiol 2006;4: 193-200.
26. Pothoulakis C, Kelly CP, Joshi MA: Saccharomyces boulardii inhibits Clostridium difficile toxin a binding and enterotoxicity in rat ileum. Gastroenterology 1993;104:1108-1115.
27. Buts J-P, De Keyser N, De Raedemaekier L: Saccharomyces boulardii enhances rat intestinal enzyme expression by endolu-minal release of polyamines. Pediatr Res 1994;36:522-527.
28. Rook GA, Brunet LR: Microbes, immunoregulation, and the gut. Gut 2005;54:317-320.
29. Fasano A, Shea-Donohue T: Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. Nat Clin Pract Gastroenterol Hepatol 2005;2:416-422.
30. Bell SG: Immunomodulation, part V: probiotics. Neonatal Netw 2007;26:57-60.
31. O'Mahony L, Feeney M, MacSharry J: Probiotics, mononuclear cells and epithelial cells: an anti-inflammatory network [abstract]. Gastroenterology 2000;118:A680.
32. de Vrese M, Marteau PR: Probiotics and prebiotics: effects on diarrhea. J Nutr 2007;137(3 Suppl 2):803S-811S.
33. Heyman M, Menard S: Probiotic microorganisms: how they affect intestinal pathophysiology. Cell Mol Life Sci 2002;59: 1151-1165.
34. Chermesh I, Eliakim R: Probiotics and the gastrointestinal tract: where we are in 2005? World J Gastroenterol 2006;12:853-857.
35. Schroder O, Gerhard R, Stein J: Antibiotic-associated diarrhea. J Gastroenterol 2006;44:193-204.
36. Bergogne-Berezin E: Treatment and prevention of antibiotic associated diarrhoea. Int J Antimicrob Agents 2000;16:521- 526.
37. McFarland LV, Surawicz CM, Greenberg RN: Prevention of beta-lactam associated diarrhoea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 1995;90:439-448.
38. Madden JA, Plummer SF, Tang J: Effect of probiotics on preventing disruption of the intestinal microflora following antibiotic therapy: a double-blind, placebo-controlled pilot study. Int Immunopharmacol 2005;5:1091-1097.
39. Vanderhoof JA, Whitney DB, Antonson DL, Hanner TL, Lupo JV, Young RJ: Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. J Pediatr 1999;135:535-537.
40. D'Souza AL RC, Cooke J, Bulpitt CJ: Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ 2002;324: 1361.
41. Wenus C, Goll R, Loken EB, Biong AS, Halvorsen DS, Florhol-men J: Prevention of antibiotic-associated diarrhoea by a fermented probiotic milk drink. Eur J Clin Nutr 2008;62:299-301.
42. Delia P, Sansotta G, Donato V, et al.: Use of probiotics for prevention of radiation-induced diarrhea. World J Gastroenterol 2007;13:912-915.
43. Demirer S, Aydintug S, Aslim B, et al.: Effects of probiotics on radiation-induced intestinal injury in rats. Nutrition 2006;22: 179-186.
44. Urbancsek H, Kazar T, Mezes I, Neumann K: Results of a double-blind, randomized study to evaluate the efficacy and safety of Antibiophilus in patients with radiation-induced diarrhoea. Eur J Gastroenterol Hepatol 2001;13:391-396.
45. Surowiec D, Kuyumjian AG, Wynd MA, Cicogna CE: Past, present, and future therapies for Clostridium difficile-associated disease. Ann Pharmacother 2006;40:2155-2163.
46. Posani T: Clostridium difficile: causes and interventions. Crit Care Nurs Clin North Am 2004;16:547-551.
47. Surawicz CM: Probiotics, antibiotic-associated diarrhea and Clostridium difficile diarrhoea in humans. Best Pract Res Clin Gastroenterol 2003;17:775-783.
48. McFarland LV, Surawicz CM, Greenberg RN: A randomized placebo controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994;271:1913-1918.
49. McFarland LV: Meta-analysis of probiotics for the prevention of traveler's diarrhea. Travel Med Infect Dis 2007;5:97-105.
50. Larsen CS, Black FT: Traveller's diarrhea. Ugeskr Laeger 2005;167:4068-4072.
51. Hilton E, Kolakowski P, Singer C, Smith M: Efficacy of Lactobacillus GG as a diarrhoeal preventive in travellers. J Travel Med 1997;4:41-43.
52. Ericsson CD: Nonantimicrobial agents in the prevention and treatment of traveler's diarrhoea. Clin Infect Dis 2005;41(Suppl 8):S557-S563.
53. Majamaa H, Isolauri E, Saxelin M, Vesikari T: Lactic acid bacteria in the treatment of acute rotavirus gastroenteritis. J Pediatr Gastroenterol Nutr 1995;20:333-338.
54. Isolauri E, Juntunen M, Rautanen T, Sillanukee P, Koivula T: A human Lactobacillus strain (L. casei sp. strain GG) promotes recovery from acute diarrhoea in children. Pediatrics 1991;88:90-97.
55. Kaila M, Isolauri E, Soppi E, Virtanen E, Laine S, Arvilommi H: Enhancement of the circulating antibody secreting cell response in human diarrhoea by a human Lactobacillus strain. Pediatr Res 1992;32:141-144.
56. Saavedra JM, Bauman NA, Oung I, Perman JA, Yolken RH: Feeding of Bifidobacterium bifidum and Streptococcus ther-mophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet 1994;344:1046-1049.
57. Boudraa G, Benbouabdellah M, Hachelaf W, Boisset M, Desjeux JF, Touhami M: Effect of feeding yoghurt versus milk in children with acute diarrhoea and carbohydrate malabsorption. J Pediatr Gastoenterol Nutr 2001;33:307-313.
58. Szymanski H, Pejcz J, Jawien M, Chmielarczyk A, Strus M, Heczko PB: Treatment of acute infectious diarrhoea in infants and children with a mixture of three Lactobacillus rhamnosus strains - a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2006;23:247-253.
59. Born P, Lersch C, Zimmerhacki B, Classen M: The Saccharomyces boulardii therapy of HIV-associated diarrhoea [letter]. Dtsch Med Wochenschr 1993;118:765.
60. Saint-Marc T, Rossello-Prats L, Touraine JL: Efficacy of Sac-charomyces boulardii in the treatment of diarrhoea in aids [letter]. Ann Intern Med 1991;142:64-65.
61. Tempe JD, Steidel AL, Blehaut H, Hasselmann M, Lutun P, Maurier F: Prevention of diarrhoea administering Saccha-romyces boulardii during continuous enteral feeding. Semaine Des Hopitaux De Paris 1983;59:1409-1412.
62. Bleichner G, Blehaut H, Mentec H, Moyse D: Saccharomyces boulardii prevents diarrhoea in critically ill tube-fed patients. A multi-centre randomized, double-blind placebo-controlled trial. Intensive Care Med 1997;23:517-523.
63. Gonzalez SN, Cardozo R, Apella MC, Olive G: Biotherapeutic role of fermented milk. Biotherapy 1994;8:129-134.
64. Harms HK, Bertele-Harms RM, Bruer-Kleis D: Enzyme substitution therapy with the yeast Saccharomyces cerevisiae in congenital sucrase isomaltase deficiency. N Engl J Med 1987;316: 1306-1309.
65. Montalto M, Curigliano V, Santoro L: Management and treatment of lactose malabsorption. World J Gastroenterol 2006;12: 187-191.
66. Savaiano DA, Abou EI, Anouar A, Smith DE, Levitt MD: Lactose malabsorption from yoghurt, pasteurised yoghurt, sweet aci-dophilus milk, and cultured milk in lactase deficient individuals. Am J Clin Nutr 1984;40:1219-1223.
67. Marteau P, Vesa T, Rambaud JC: Lactose maldigestion. In: Probiotics (Fuller R, ed.). Chapman & Hall, London, 1997, pp. 65-68.
68. Vesa TH, Marteau P, Zidi S, Briet F, Pochart P, Rambaud JC: Digestion and tolerance of lactose from yoghurt and different semi-solid fermented dairy products containing Lactobacillus acidophilus and bifidobacteria in lactose maldigesters - is bacterial lactase important? Eur J Clin Nutr 1996;50:730-733.
69. Gaon D, Doweck Y, Gomez Zavaglia A, Ruiz Holgado A, Oliver G: Lactose digestion by milk fermented with Lactobacillus aci-dophilus and Lactobacillus casei of human origin. Medicina (B Aires) 1995;55:237-242.
70. Markowitz JE, Bengmark S: Probiotics in health and disease in the pediatric patients. Pediatr Clin North Am 2002;49:127-141.
71. Scholmerich J: Treatment of inflammatory bowel disease. Schweiz Rundsch Med Prax 2007;96:337-343.
72. Harris LA, Chang L: Irritable bowel syndrome: new and emerging therapies. Curr Opin Gastroenterol 2006;22:128-135.
73. Shanahan F: Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2005;288: G417-G421.
74. Cummings JH, Kong SC: Probiotics, prebiotics and antibiotics in inflammatory bowel disease. Novartis Found Symp 2004;263:99-111.
75. Baumgart DC, Dignass AU: Current biological therapies for inflammatory bowel disease. Curr Pharm Des 2004;10:4127-4147.
76. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M: Double-blind comparison of an oral E. coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997;11:853-858.
77. Tursi A, Brandimarte G, Giorgetti GM, Forti G, Modeo ME, Gigliobianco A: Low-dose balsalazide plus a high-potency pro-biotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit 2004;10:PI126-PI131.
78. Gupta P, Andrew H, Kirschner BS, Guandalini S: Is Lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr 2000;31:453-457.
79. Sheil B, Shanahan F, O'Mahony L: Probiotic effects on inflammatory bowel disease. J Nutr 2007;137(3 Suppl 2):819S-824S.
80. Penner RM, Madsen KL, Fedorak RN: Postoperative Crohn's disease. Inflamm Bowel Dis 2005;11:765-777.
81. Marteau P, Lemann M, Seksik P: Ineffectiveness of Lactobacil-lus johnsonii la1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double-blind, placebo-controlled getaid trial. Gut 2005;23:443-454.
82. Lesbros-Pantoflickova D, Corthesy-Theulaz I, Blum AL: Helicobacter pylori and probiotics. J Nutr 2007;137(3 Suppl 2): 812S-818S.
83. Tong JL, Ran ZH, Shen J, Zhang CX, Xiao SD: Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2007;25:155-168.
84. Michetti P, Dorta G, Wiesel PH, et al.: Effect of whey-based culture supernatant of Lactobacillus acidophilus (johnsonii) La1 on Helicobacter pylori infection in humans. Digestion 1999; 60:203-209.
85. Felley CP, Corthésy-Theulaz I, Sipponen P, et al.: Favourable effect of an acidified milk (LC-1) on Helicobacter pylori gastritis in man. Eur J Gastroenterol Hepatol 2001;13:25-29.
86. Kalliomaki M, Isolauri E: Pandemic of atopic diseases - a lack of microbial exposure in early infancy? Curr Drug Targets Infect Disorders 2002;2:193-199.
87. Noverr MC, Huffnagle GB: Does the microbiota regulate immune responses outside the gut? Trends Microbiol 2004;12:562-568.
88. Furrie E: Probiotics and allergy. Proc Nutr Soc 2005;64: 465-469.
89. Bischoff S, Crowe SE: Food allergy and the gastrointestinal tract. Curr Opin Gastroenterol 2004;20:156-161.
90. Feleszko W, Jaworska J, Hamelmann E: Toll-like receptors - novel targets in allergic airway disease (probiotics, friends and relatives). Eur J Pharmacol 2006;533:308-318.
91. Vandenbulcke L, Bachert C, Van Cauwenberge P, Claeys S: The innate immune system and its role in allergic disorders. Int Arch Allergy Immunol 2006;139:159-165.
92. Matricardi PM, Bonini S: High microbial turnover rate preventing atopy: a solution to inconsistencies impinging on the hygiene hypothesis? Clin Exp Allergy 2000;30:1506-1510.
93. Morata de Ambrosini V, Gonzales S, de Ruiz Holgado AP, Oliver G: Study of the morphology of the cell walls of some strains of lactic acid bacteria and related species. J Food Prot 1998;61:557-562.
94. Sanfilippo L, Li CK, Seth R, Balwin TJ, Menozzi MG, Mahida YR: Bacteroides fragilis enterotoxin induces the expression of IL-8 and transforming growth factor-beta (TFG-β) by human colonic epithelial cells. Clin Exp Immunol 2000;119:456-463.
95. Xavier RJ, Podolsky DK: Microbiology: how to get along - friendly microbes in a hostile world. Science 2000;289:1483-1484.
96. Weiner HL: Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol Today 1997;18:335-343.
97. Niers LE, Rijkers GT, Timmerman HM, Knol EF, Hoekstra MO: Probiotics for cow's milk allergy: classification after intervention. J Allergy Clin Immunol 2005;115:423-424.
98. He F, Ouwehand AC, Isolauri E, Hashimoto H, Benno Y, Salmi-nen S: Comparison of mucosal adhesion and species identification of Bifidobacterium isolated from healthy and allergic infants. FEMS Immunol Med Microbiol 2001;30:43-47.
99. Mack DR, Michail S, Wei S, McDougall L, Hollingsworth MA: Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol 1999;276:G941-G950.
100. Reid G, Sanders M, Gaskins HR: New specific paradigms for probiotics and prebiotics. J Clin Gastroenterol 2003;37:105-118.
101. Maassen CB, Holten-Neelen C, Balk F, et al.: Strain-dependent induction of cytokine profiles in the gut by orally administered Lactobacillus strains. Vaccine 2000;18:2613-2623.
102. Haller D, Blum S, Bode C, Hammes WP, Schiffrin EJ: Activation of human peripheral blood mononuclear cells by nonpathogenic bacteria in vitro: evidence of NK cells as primary targets. Infect Immun 2000;68:752-759.
103. Miettinen M, Vuopio Varikila J, Varkila K: Production of human necrosis factor alpha, IL-6, and IL-10 is induced by lactic acid bacteria. Infect Immun 1996;64:5403-5405.
104. Koop-Hooliham L: Prophylactic and therapeutic uses of probiotics: a review. J Am Diet Assoc 2001;101:229-237.
105. Galdeano CM, Perdigon G: The probiotic bacterium Lactobacillus casei induces activation of the gut mucosal immune system through innate immunity. Clin Vaccine Immunol 2006;13: 219-226.
106. Sheil B, McCarthy J, O'Mahony L: Is the mucosal route administration essential for probiotic function? Subcutaneous administration is associated with murine colitis and arthritis. Gut 2004;53:694-700.
107. Ogawa T, Asai Y, Tamai R, et al. : Natural killer cell activities of synbiotic Lactobacillus casei ssp. casei in conjunction with dextran. Clin Exp Immunol 2006;143:103-109.
108. Shida K, Takahashi R, Iwadate E: Lactobacillus casei strain Shirota suppresses serum immunoglobulin E and immunoglobulin G1 responses and systemic anaphylaxis in a food allergy model. Clin Exp Allergy 2002;32:563-570.
109. Dieleman LA, Goerres MS, Arends A: Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut 2003;52:370-376.
110. Madsen KL, Malfair D, Gray D, Doyle JS, Jewell LD, Fedorak RN: Interleukin-10 gene-deficient mice develop a primary intestinal permeability defect in response to enteric microflora. In flamm Bowel Dis 1999;5:262-270.
111. Ulisse S, Gionchetti P, D'Alo S: Expression of cytokines, in-ducible nitric oxide synthase, and matrix metalloproteinases in pouchitis. Effects of probiotic treatment. Am J Gastroenterol 2001;96:2691-2699.
112. Li Z, Yang S, Lin H: Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003;37:343-350.
113. Reid G: Probiotic agents to protect the urogenital tract infection. Am J Clin Nutr 2001;73(2 Suppl):437S-444S.
114. Reid G, Bruce AW: Probiotics to prevent urinary tract infections: the rationale and evidence. World J Urol 2005;31:1-5.
115. Hoesl CE, Altwein JE: The probiotic approach: an alternative treatment option in urology. Eur Urol 2005;47:288-296.
116. Tomoda T, Nakano Y, Kageyama T: Intestinal Candida overgrowth and Candida infection in patients with leukemia: effect of Bifidobacterium administration. Bifidobacteria Microflora 1998;7:71-74.
117. Reid G, Bruce AW: Low vaginal pH and urinary tract infection. Lancet 1995;346:1704.
118. Asahara T, Nomoto K, Watanuki M, Yokokura T: Antimicrobial activity of interurethrally administered probiotic Lactobacillus casei in a murine model of Escherichia coli urinary tract infection. Antimicrob Agents Chemother 2001;45:1751-1760.
119. Anukam KC, Osazuwa E, Osemene GI, Ehigiagbe F, Bruce AW, Reid G: Clinical study comparing probiotic Lactobacillus GR-1 and RC-14 with metronidazole vaginal gel to treat symptomatic bacterial vaginosis. Microbes Infect 2006;8:2772-2776.
120. Anukam K, Osazuwa E, Ahonkhai I, et al. : Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial. Microbes Infect 2006;8:1450-1454.
121. 2-producing lactobacilli and bacterial vaginosis in pregnant woman. Clin Infect Dis 1993;16 (Suppl 4):S273-S281.
122. Cauci S, Guaschino S, Aloysio DD: Interrelationships of inter-leukin-8 with interleukin-1β and neutrophils in vaginal fluid of healthy and bacterial vaginosis positive women. Mol Hum Reprod 2003;9:53-58.
123. Cauci S, Hitti J, Noonan C: Vaginal hydrolytic enzymes, immunoglobulin A against Gardnerella vaginalis toxin, and risk of early preterm birth among women in preterm labor with bacterial vaginosis or intermediate flora. Am J Obstet Gynecol 2002;187:877-881.
124. Cauci S, Thorsen P, Schendel DE: Determination of immunoglobulin A against Gardnerella vaginalis hemolysin, sial-idase and prolidase activities ion vaginal fluid: implications for adverse pregnancy outcomes. J Clin Microbiol 2003;41:435-438.
125. Reid G, Bocking A: The potential for probiotics to prevent bacterial vaginosis and preterm labor. Am J Obstet Gynecol 2003;189:1202-1208.
126. Reid G, Habash M: Urogenital Microflora and Urinary Tract Infections. Kluwer, London, 1998, pp. 423-440.
127. Hauth JC, Goldenberg RL, Andrews WW, DuBard MB, Copper RL: Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. N Engl J Med 1995;333:1732-1736.
128. 2-generating lac-tobacilli. J Infect Dis 1991;164:94-110.
129. Parent D, Bossens M, Bayot D: Therapy of bacterial vaginosis using exogenously-applied Lactobacillus acidophili and a low dose of estriol: a placebo-controlled multicentric clinical trial. Arzneimittelforschung 1996;46:68-73.
130. Hallén A, Jarstrand C, Påhlson C: Treatment of bacterial vaginal disease with lactobacilli. Sex Transm Dis 1992;19: 146-148.
131. Reid G, McGroarty J, Tomeczek L: Identification and plasmid profiles of Lactobacillus species from the vagina of 100 healthy women. FEMS Immunol Med Microbiol 1996;15:23-26.
132. Gardiner G, Heinemann C, Baroja ML: Oral administration of the probiotic combination Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 for human intestinal applications. Int Dairy 2002;12:191-196.
133. Cadieux P, Burton J, Kang CY, et al. : Lactobacillus strains and vaginal ecology. JAMA 2002;287:1940-1941.
134. Wollowski I, Rechkemmer G, Pool-Zobel BL: Protective role of probiotics and prebiotics in colon cancer. Am J Clin Nutr 2001;73(2 Suppl):451S-455S.
135. Goldin BR, Gualtieri L, Moore RP: The effect of Lactobacillus GG on the initiation and promotion of dimethyl-hydrazine induced intestinal tumours in the rat. Nutr Cancer 1996;25: 197-204.
136. Morotomi M: Properties of Lactobacillus casei Shirota strain as probiotics. Asia Pac J Clin Nutr 1996;5:29-30.
137. Rafter J, Bennett M, Caderni G, et al. : Dietary synbiotics reduce cancer risk factors in polypectomized and colon cancer patients. Am J Clin Nutr 2007;85:488-496.
138. Nguyen TD, Kang JH, Lee MS: Characterization of Lactobacillus plantarum PH04, a potential probiotic bacterium with cholesterol-lowering effects. Int J Food Microbiol 2007;113: 358-361.
139. Liong MT, Shah NP: Acid and bile tolerance and cholesterol removal ability of lactobacilli strains. J Dairy Sci 2005;88:55-66.
140. Andersson H, Bosaeus I, Ellegard L, et al. : Effect of low-fat milk and fermented low-fat milk on cholesterol absorption and excretion in ileostomy subjects. Eur J Clin Nutr 1995;49: 274-281.
141. De Smet I, De Boever P, Verstraete W: Cholesterol lowering in pigs through enhanced bacterial bile salt hydrolase activity. Br J Nutr 1998;79:185-194.
142. Hepner G, Freid R, Jeor SS, Fusetti L, Morin R: Hypocholes-terolemic effect of yoghurt and milk. Am J Clin Nutr 1979; 32:19-24.
143. Doron S, Gorbach SL: Probiotics: their role in the treatment and prevention of disease. Expert Rev Anti Infect Ther 2006;4:261-275.
144. Bayona Gonzalez A, Lopez Camara V, Castellanos AG: Prevention of caries with Lactobacillus (final results of a clinical trial on dental caries with killed Lactobacillus [Streptococcus and Lactobacillus] given orally). Pract Odontol 1990;11:37-39, 42-43, 45-46.
145. Grangette C, Müller-Alouj H, Goudercourt D, Geoffroy MC, Turneer M, Mercenier A: Mucosal immune responses and protection against tetanus toxin after intranasal immunization with recombinant Lactobacillus plantarum. Infect Immun 2001;69: 1547-1553.
146. Hatakka K, Savilahti E, Ponka A: Effect of long term consumption of probiotic milk on infections in children attending day care centres: double-blind, randomized trial. BMJ 2001; 322:1327-1329.
147. Jauhiainen T, Korpela R: Milk peptides and blood pressure. J Nutr 2007;137(3 Suppl 2):825S-829S.
148. Aihara K, Kajimoto O, Hirata H, Takahashi R, Nakamura Y: Effect of powdered fermented milk with Lactobacillus helveticus on subjects with high-normal blood pressure or mild hypertension. J Am Coll Nutr 2005;24:257-265.
149. Lieske JC, Goldfarb DS, De Simone C, Regnier C: Use of a pro-biotic to decrease enteric hyperoxaluria. Kidney Int 2005;68: 1244-1249.
150. Hoesl CE, Altwein JE: The probiotic approach: an alternative treatment option in urology. Eur Urol 2005;47:288-296.
151. Howard JC, Reid G, Gan BS: Probiotics in surgical wound infections: current status. Clin Invest Med 2004;27:274-281.
152. Valdez JC, Peral MC, Rachid M, Santana M, Perdigon G: Interference of Lactobacillus plantarum with Pseudomonas aeruginosa in vitro and in infected burns: the potential use of probiotics in wound treatment. Clin Microbiol Infect 2005;11:472-479.
153. Komaroff AL, Fagioli LR, Geiger AM: An examination of working case definition of chronic fatigue syndrome. Am J Med 1996;100:56-64.
154. Butt HL, Dunstan RH, McGregor NR: Faecal microbial growth inhibition in chronic fatigue/pain patients [abstract]. In: Proceedings of the AHMF International Clinical and Scientific Conference. Alison Hunter Memorial Foundation, Sydney, Australia, 1998.
155. Moore WEC, Cato EP, Holdeman LV: Some current concepts in intestinal bacteriology. Am J Clin Nutr 1978;31(10 Suppl): S33-S42.
156. Manuel Y, Keenoy B, Moorkens G: Magnesium status and parameters of the oxidant-antioxidant balance in patients with chronic fatigue syndrome: effects of supplementation with magnesium. J Am Coll Nutr 2000;19:374-382.
157. Manuel Y, Keenoy B, Moorkens G: Antioxidant status and lipoprotein peroxidation of chronic fatigue syndrome. Life Sci 2001;68:2037-2049.
158. Ockerman P: Antioxidant treatment of chronic fatigue syndrome. Clin Pract Altern Med 2000;1:88-91.
159. Logan AC, Katzman M: Major depressive disorder: probiotics may be an adjuvant therapy. Med Hypotheses 2005;64:533-538.
160. Weaver CM, Liebman M: Biomarkers of bone health appropriate for evaluating functional foods designed to reduce risk of osteoporosis. Br J Nutr 2002;88(Suppl 2):S225-S232.
161. Tsugawa N, Yamabe T, Takeuchi A: Intestinal absorption of calcium from calcium ascorbate in rats. J Bone Miner Metab 1999; 17:30-36.
162. Van den Heuvel E, Muys T, Van Dokskum W, Schaafsma G: Oligofructose stimulates calcium absorption in adolescents. Am J Clin Nutr 1999;69:544-548.
163. Yadav H, Jain S, Sinha PR: Antidiabetic effect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei in high fructose fed rats. Nutrition 2007;23:62-68.
164. Ludwig DS, Pereira MA, Kroenke CH: Dietary fiber, weight gain and cardiovascular disease risk factors in young adults: the CARDIA Study. JAMA 1999;282:1539-1546.
165. Saarela M, Mogensen G, Fonden R, Matto J, Mattila-Sandholm T: Probiotic bacteria: safety, functional and technological properties. J Biotechnol 2000;84:197-215.
166. Henriksson A, Borody T, Clancy R: Probiotics under the regulatory microscope. Expert Opin Drug Safety 2005;4:1135-1143.
167. Prakash S, Martoni C: Toward a new generation of therapeutics: artificial cell targeted delivery of live cells for therapy. Appl Biochem Biotechnol 2006;128:1-22.
168. Sand J, Nordback I: Probiotics in severe acute pancreatitis. Lancet 2008;371:634-635.
169. Kayser FH: Safety aspects of enterococci from the medical point of view. Int J Food Microbiol 2003;88:255-262.
170. Koch S, Hufnagel M, Huebner J: Treatment and prevention of enterococcal infections - alternative and experimental approaches. Exp Opinion Biol Ther 2004;4:1519-1531.
171. Koch S, Hufnagel M, Theilacker C, Huebner J: Enterococcal infections: host response, therapeutic, and prophylactic possibilities. Vaccine 2005;22:822-830.
172. Salminen MK, Rautelin H, Tynkkynen S, et al. : Lactobacillus bacteremia, species identification, and antimicrobial susceptibility of 85 blood isolates. Clin Infect Dis 2006;42:e35-e44.
173. Report of a Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria. World Health Organization & Food and Agricultural Organization of the United Nations, London, ON, Canada, 2001.
174. Joint FAO/WHO Working Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food. World Health Organization & Food and Agricultural Organization of the United Nations, London, ON, Canada, 2002.
175. Agostoni C, Axelsson I, Braegger C, et al. : Probiotic bacteria in dietetic products for infants: a commentary by the ESPGHAN Committee on Nutrition. J Pediatr Gastroenterol Nutr 2004;38:365-374.
176. Kaur IP, Garg A, Geetha T, Agrawal R: Entrapment of probi-otic bacteria within alginate HPMC floating beads, their survival and effectiveness against ethanol-induced ulcers in rats. Int J Probiotics & Prebiotics 2007;2:141-148.